Navigation Links
Improvement in prediction of blood clots in cancer patients
Date:9/9/2010

(WASHINGTON, September 9, 2010) For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology. VTE, the formation of blood clots in the veins, develops in up to 20 percent of cancer patients and is one of the leading causes of death among this patient population. Patients with hematologic malignancies (blood cancers), particularly those with lymphoma and multiple myeloma, have relatively high rates of VTEresults from this study found that 7.2 percent of lymphoma patients and 7.4 percent of the total study population developed VTE, compared to an estimated general population incidence rate of .001 percent.1

"Because the risk of VTE is not equal in all cancer patients and anticoagulation in cancer patients results in a higher risk of bleeding complications, categorizing cancer patients according to their VTE risk is important," said Ingrid Pabinger, MD, professor at the Medical University of Vienna and lead author of the study. Patients with high risk of VTE may benefit from routine thrombophrophylaxis, preventive treatment for blood clotting, while low-risk patients tend to have a higher bleeding risk and may not be the best candidates for routine anticoagulation treatments.

Although there is a current risk prediction model for VTE in cancer patients, which includes factors such as site of cancer, body mass index, platelet and leukocyte counts, and hemoglobin levelall known to increase the risk of cancer-associated VTEthe new model also incorporates two new biomarkers, soluble P-selectin (sP-selectin) and D-dimer, to further stratify patients into high- and low-risk groups. sP-selectin is a cell adhesion molecule that promotes blood clot formation and D-dimer is a protein found in the blood that is used to detect abnormal blood clot formation and breakdown. Both have been previously identified as predictive biomarkers for cancer-associated VTE and their addition into the risk prediction model improves the accuracy of the classification of the patients into different risk categories. According to this new risk scoring model, about one-third (35 percent) of cancer patients in the highest risk category developed VTE during the study, as opposed to only one percent of patients in the lowest risk category.

In this study, researchers examined 819 cancer patients enrolled in the Vienna Cancer and Thrombosis Study (CATS), an ongoing prospective observational study performed at the Medical University of Vienna, between October 2003 and December 2008. Cancer types included: brain, breast, lung, stomach, colorectal, pancreatic, kidney, prostate, and hematologic malignancies such as myeloma and lymphoma.

"Our expanded model demonstrates that cancer patients at a very high risk of VTE can be defined more precisely," said Cihan Ay, MD, hematology fellow at the Clinical Division of Hematology and Hemostaseology at the Medical University of Vienna and co-author of the study. "This new model can help clinicians tailor their anticoagulant therapy and improve blood clotting prevention, which will maximize the clinical benefit and cost-effectiveness of disease prevention and minimize the risk of bleeding complications."


'/>"/>

Contact: Lindsey Love
llove@hematology.org
202-552-4925
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. New antiviral drug shows promise for dramatic improvement in hepatitis C treatment
2. New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment
3. Drug study shows improvement in major orthopedic surgery care
4. Green And Greener Survey Shows Hospitals Embrace Environmentally Sustainable Practices, Though Room for Improvement Remains
5. Network Latency Improvement Creates One of the Fastest Routes between Chicago and Newark/New York City
6. Comparison of available breast cancer risk assessment tools shows room for improvement
7. Global Summit on International Breast Health Targets Breast Health Improvements in Developing Countries, June 9-11, 2010, in Chicago
8. Patient-reported outcomes study shows improvements in quality of life among patients after 1 year of treatment with TYSABRI
9. Cosmetic and Plastic Surgery Web Site Announces Improvements to the Patient Process of Finding Cosmetic Doctors in Their Area
10. Long Island Children's Orthodontist Announces Office Improvements And New Staff Member
11. Lifesaving Bills Filed in Florida Legislature to Guarantee Patient Safety Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in helping their ... and how to avoid being bitten this spring. , The official tick season ... small spider-like insects, are known for attaching themselves to their prey while they feed ...
(Date:5/24/2016)... ... 24, 2016 , ... Design Concepts , a national ... Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was designed working with ... for this often overlooked neighborhood. Located at 609 E. 6th Street, Pueblo’s newest ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... imaging; multiplex immunoassays are widely used for cell and protein analysis. Keeping updated ... their quality and efficiency in these areas. , LabRoots introduces a new ...
(Date:5/24/2016)... ... May 24, 2016 , ... NutraPre today ... beverage for pregnant women to prevent morning sickness and promote overall heath. Engineered ... the look and taste of water. , “Imagine a pregnancy without morning sickness,” ...
(Date:5/23/2016)... NY (PRWEB) , ... May 23, 2016 , ... On ... Ferdico took the time to summarize the weight loss process: , New patients have ... Body Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There are ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 Gamida Cell, a leader ... cancer and orphan genetic diseases, announced today it has ... from the Israel Innovation Authority (formerly the Office of ... and Industry. The mission of the Israel Innovation Authority ... including science and technology, while stimulating economic growth. ...
(Date:5/20/2016)... , May 20, 2016 ... veteran investors believe that the industry is not far ... and today ActiveWallSt.com featured the following four equities: Anacor ... (NASDAQ: ATHX ), Aralez Pharmaceuticals Inc. (NASDAQ: ... INFI ). Sign up for your free ...
(Date:5/19/2016)... PARIS , May 19,2016 ... Activities at Digestive Disease Week Meeting and 91 ... Society Mauna Kea Technologies (Euronext: MKEA, ... laser endomicroscopy platform, today announced that its Cellvizio ... meeting focused on gastroenterology during the month of ...
Breaking Medicine Technology: